Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Reinvestment Rate
Shanghai RAAS Blood Products Co Ltd Class A cash flow reinvestment rate. Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow Reinvestment Rate of 0.41x as of March 2025, reinvesting CN¥317.67 Million (capex CN¥62.51 Million plus investments CN¥255.16 Million) from operating cash flow of CN¥775.56 Million. Explore cash flow to debt ratio of Shanghai RAAS Blood Products Co Ltd Clas to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shanghai RAAS Blood Products Co Ltd Class A (2005–2023)
Cash flow reinvestment rate of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2023. Historical reinvestment intensity for Shanghai RAAS Blood Products Co Ltd Class A across 18 annual periods. Explore 002252 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Reinvestment Rate by Year (2005–2023)
Shanghai RAAS Blood Products Co Ltd Class A cash flow reinvestment rate by year from 2005 to 2023. Year-by-year capital reinvestment analysis for Shanghai RAAS Blood Products Co Ltd Class A. For the full cash flow conversion analysis, see how efficiently does Shanghai RAAS Blood Products Co Ltd Clas generate cash.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.49x | CN¥1.12 Billion | CN¥2.28 Billion | CN¥450.80 Million | ▼ -27.5% |
| 2022 | 0.68x | CN¥1.17 Billion | CN¥1.73 Billion | CN¥225.73 Million | ▲ +8.0% |
| 2021 | 0.63x | CN¥814.12 Million | CN¥1.29 Billion | CN¥204.61 Million | ▲ +17.7% |
| 2020 | 0.53x | CN¥624.78 Million | CN¥1.17 Billion | CN¥251.76 Million | ▲ +172.1% |
| 2019 | 0.20x | CN¥171.43 Million | CN¥872.69 Million | CN¥154.84 Million | ▼ -94.6% |
| 2018 | 3.66x | CN¥959.60 Million | CN¥262.50 Million | CN¥156.94 Million | ▼ -42.4% |
| 2017 | 6.35x | CN¥1.71 Billion | CN¥268.76 Million | CN¥157.84 Million | ▲ +273.3% |
| 2016 | 1.70x | CN¥1.08 Billion | CN¥638.22 Million | CN¥147.49 Million | ▲ +791.5% |
| 2015 | 0.19x | CN¥145.39 Million | CN¥762.42 Million | CN¥145.39 Million | ▲ +36.6% |
| 2014 | 0.14x | CN¥65.06 Million | CN¥465.96 Million | CN¥65.06 Million | ▼ -75.4% |
| 2012 | 0.57x | CN¥149.70 Million | CN¥263.46 Million | CN¥149.70 Million | ▼ -42.8% |
| 2011 | 0.99x | CN¥176.80 Million | CN¥178.03 Million | CN¥176.80 Million | ▲ +122.9% |
| 2010 | 0.45x | CN¥89.21 Million | CN¥200.21 Million | CN¥89.21 Million | ▼ -15.2% |
| 2009 | 0.53x | CN¥60.99 Million | CN¥116.01 Million | CN¥60.99 Million | ▲ +93.6% |
| 2008 | 0.27x | CN¥29.23 Million | CN¥107.64 Million | CN¥29.23 Million | ▲ +95.1% |
| 2007 | 0.14x | CN¥24.46 Million | CN¥175.71 Million | CN¥24.46 Million | ▼ -38.3% |
| 2006 | 0.23x | CN¥12.08 Million | CN¥53.58 Million | CN¥12.08 Million | ▼ -43.8% |
| 2005 | 0.40x | CN¥21.69 Million | CN¥54.02 Million | CN¥21.69 Million | — |